Rheumatology revenue sits in two very different places: the office visit, where complex autoimmune disease drives high level evaluation and management coding, and the infusion suite, where a single biologic dose can carry more revenue risk than a week of visits. The infusion side is where most rheumatology claims fail, because the drug, the dose, the units, and the authorization all have to agree exactly, and any one of them can change between scheduling and the day of treatment.
MedPlus RCM provides medical billing, coding, credentialing, and denial management for rheumatology practices, built around biologics, infusions, and the long term medication management that defines the specialty.

Rheumatology billing challenges

Biologic infusion billing starts with authorization. High cost infused drugs almost always require prior authorization before administration, and the approval must cover the exact drug, dose, frequency, and service dates. A weight based dose that steps up after new labs changes the billable units, because units on the claim equal the administered dose divided by the amount in the J-code descriptor. If the authorization still shows the old dose, the claim denies even though the treatment was correct. Reauthorization tracking matters just as much: a patient infused on a lapsed approval is an uncollectible visit.
Drug and administration coding must be billed as a pair. The J-code identifies the drug and the administration code identifies how it was given, and both must reconcile to the National Drug Code and the dose in the infusion note. Common rheumatology biologics each carry their own J-code, for example infliximab, rituximab, abatacept, and tocilizumab, and each biosimilar version carries a distinct code of its own. Payer preference policies for biosimilars change, so the product dispensed and the product billed must match, and discarded drug from single use vials must be reported with the JW modifier, or JZ when there is no wastage.
Office based rheumatology brings its own rules. Evaluation and management levels are driven by medical decision making or total time, which matters for complex autoimmune patients whose visits involve lab review, medication counseling, and prior authorization discussions. Joint aspiration and injection procedures are coded with attention to guidance rules and bundling, and injection series such as hyaluronic acid for knee osteoarthritis carry series rules, including a modifier for subsequent injections in a series. Step therapy is a further hurdle: payers commonly require documented failure of less expensive therapies before approving a biologic, and that documentation must be in the record before the authorization request, not assembled during an appeal.

What MedPlus RCM handles for rheumatology practices

  • End-to-end medical billing. Charge entry, claim scrubbing, submission, payment posting, and patient billing, the full cycle.
  • Medical coding. Certified coders assign current ICD-10, CPT, and HCPCS codes matched to your documentation and specialty.
  • Provider credentialing and enrollment. End-to-end enrollment with commercial payers and Medicare, plus re-credentialing maintenance.
  • Denial management and recovery. Every denial investigated to root cause, corrected, and appealed with documentation.
  • A/R recovery. Aged and outstanding balances audited and pursued, including balances already written off where the appeal window is still open.
  • Financial reporting. Clean claim rates, collections, denial patterns, and A/R aging visible by payer and provider.
    We serve rheumatology practices nationwide, including infusion centers and office based clinics, across rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis, gout, and vasculitis.

Results rheumatology practices can check

MedPlus RCM maintains a 99% clean claim rate and keeps client accounts receivable under 30 days. Pricing is a performance-based percentage of successfully collected revenue: if you don’t get paid, we don’t get paid. We are 100% HIPAA compliant, and onboarding takes 2 to 4 weeks depending on practice size, with no disruption to your daily cash flow.

Frequently asked questions

Why do biologic infusion claims deny?
The leading causes are authorization mismatches, unit mismatches between the authorized dose and the administered dose, missing wastage modifiers, and biosimilar code mismatches. All four are caught by reconciling the authorization, the pharmacy preparation, and the claim before the drug is given.
What happens when a patient’s dose changes?
The authorization must change with it. A dose step-up should trigger an updated authorization promptly, so the approval on file reflects what will actually be billed.
Can a biosimilar be billed under the reference product’s code?
No. Each biosimilar has its own HCPCS code, and payer preference policies determine which product is covered, so the claim must name the exact product dispensed.
How is a rheumatology office visit leveled?
By medical decision making or total time, which suits complex autoimmune visits that involve lab review, medication management, and counseling. Time spent on those activities counts toward the level when it is documented.
Do you track authorization expirations?
Yes. Authorization expiry dates and remaining units are tracked so no patient is infused on a lapsed approval.

Get a free financial audit

Find out where your rheumatology practice is losing revenue. Request a free financial audit and our specialists will review your claims, denials, and A/R.
Request your free financial audit